UK Biotechs Still Set On Cashing Out

Homegrown Global Player Yet To Take Root

06 Feb 2023

Excluding the multinational majors AstraZeneca and GSK, the UK has yet to produce a truly successful scaled pharma company, despite having boasted several innovative start-ups. Whether that represents a negative, however, is a matter for debate.

The trend of promising UK drugmakers being acquired for millions of dollars by US majors continued apace last year – a sign, some would argue, that the country's biotech sector will never develop into the fully integrated industry that perhaps its drug discovery expertise merits.

In 2022, some of the biggest players in US pharma crossed the Atlantic to get hold of prime UK assets....